|Glen S. Kwon, Ph.D.
Co-Founder and Chief Scientific Officer
Prof. Kwon is a faculty member at the University of Wisconsin-Madison where he holds the Jens T. Carstensen Distinguished Chair at the School of Pharmacy. He is a member of the Experimental Therapeutics Program at the UW-Madison Carbone Cancer Center, an Adjunct Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta and a member of the Board of Scientific Advisors in CRS. He is a Fellow of the American Association of Pharmaceutical Scientists (2012). Prof. Kwon was a Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellow at the Institute of Advanced Biomedical Engineering and Science at Tokyo Women’s Medical University in Tokyo, Japan from 1991 to 1993 and an Assistant Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta in Edmonton, Canada from 1993 to 1997. He received the Jorge Heller Journal of Controlled Release/Controlled Release Society (CRS) Outstanding Paper Award in 1994 and the CRS Young Investigator Research Achievement Award in 2003. He was the editor of Polymeric Drug Delivery Systems in 2005 and co-editor of Nanotechnology in Drug Delivery in 2008. He served on the Gene and Drug Delivery Study Section at NIH from 2005 to 2009. Dr. Kwon served as a Consultant at Nanocarrier Inc., PhaseRx and Intezyne.
|Kevin R. Kozak, M.D., Ph.D
Co-Founder and Chief Medical Officer
Dr. Kozak is the Chief of Radiation Oncology at Mercy Regional Cancer Center. Dr. Kozak is an Honorary Fellow in the Department of Medical Physics at the University of Wisconsin-Madison. He also was an Assistant Professor in the Department of Human Oncology at the University of Wisconsin-Madison (2008-13). He served as Chief Medical Officer for Cellectar Biosciences (2013-2016). He is a Board Certified Radiation Oncologist from the American Board of Radiology. Dr. Kozak earned his Ph.D. in Biochemistry and M.D. degree from Vanderbilt University and completed a post-doctoral fellowship and radiation oncology clinical training at the Harvard Radiation Oncology Program.
|Abdalla A. Saad
Co-Founder, President & Chief Executive Officer
Mr. Saad has been instrumental in launching Co-D Therapeutics where he is involved in business development, fund raising, and technology licensing. He assisted in securing funding through WARF’s Accelerator Program to develop Triolimus. Prior to Co-D, Mr. Saad held positions as a research scientist at the University of Wisconsin-Madison where he developed expertise in drug screening techniques and technology evaluation. Mr. Saad has worked for both the Wisconsin Entrepreneurs’ Network and the Venture Capital Group at Burrill & Company. Mr. Saad received his B.S. in Zoology and M.S. in Biotechnology from the University of Wisconsin-Madison.